Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes
Authors:
Open Access
- 5 February 2024
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 30 (1) , 1-15
Abstract
Background: Fluvoxamine is one of the selective serotonin reuptake inhibitors (SSRIs) that are regarded as the first-line drugs to manage mental disorders. It has been also recognized with the potential to treat inflammatory diseases and viral infection. However, the effect of fluvoxamine on autoimmune diseases, particularly type 1 diabetes (T1D) and the related cellular and molecular mechanisms, are yet to be addressed. Method: Herein in this report, we treated NOD mice with fluvoxamine for 2 weeks starting from 10-week of age to dissect the impact of fluvoxamine on the prevention of type 1 diabetes. We compared the differences of immune cells between 12-week-old control and fluvoxamine-treated mice by flow cytometry analysis. To study the mechanism involved, we extensively examined the characteristics of CD4+ T cells with fluvoxamine stimulation using RNA-seq analysis, real-time PCR, Western blot, and seahorse assay. Furthermore, we investigated the relevance of our data to human autoimmune diabetes. Result: Fluvoxamine not only delayed T1D onset, but also decreased T1D incidence. Moreover, fluvoxamine-treated NOD mice showed significantly attenuated insulitis coupled with well-preserved β cell function, and decreased Th1 and Th17 cells in the peripheral blood, pancreatic lymph nodes (PLNs), and spleen. Mechanistic studies revealed that fluvoxamine downregulated glycolytic process by inhibiting phosphatidylinositol 3-kinase (PI3K)-AKT signaling, by which it restrained effector T (Teff) cell differentiation and production of proinflammatory cytokines. Conclusion: Collectively, our study supports that fluvoxamine could be a viable therapeutic drug against autoimmunity in T1D setting.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82100892, 81920108009, 82070808)
- Postdoctoral Science Foundation of China (54000-0106540080)
- Department of Science and Technology of Hubei Province Program Project (2020DCD014)
This publication has 42 references indexed in Scilit:
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Fluvoxamine versus other anti-depressive agents for depressionCochrane Database of Systematic Reviews, 2010
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 DiabetesDiabetes Care, 2010
- Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D ScalesBMC Musculoskeletal Disorders, 2009
- IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survivalBlood, 2008
- THE NOD MOUSE: A Model of Immune DysregulationAnnual Review of Immunology, 2005
- IL-1β, IFN-γ and TNF-α increase vulnerability of pancreatic beta cells to autoimmune destructionJournal of Autoimmunity, 2003
- FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITORBritish Journal of Pharmacology, 1977